In conclusion, we identified circulating VEGFR3 as a novel biomarker for predicting pCR through proteomic analysis of plasmas from a mouse model of rectal cancer, and further confirmed increased VEGFR3 levels in pretreatment plasmas from non-pCR LARC patients compared to pCR LARC patients. This evidence concerns the gene FLT4 and rectal cancer.